An unusual reductive ring-opening reaction in the title compounds, of the phthalimide group with sodium hydride in anhydrous DMF is observed for the first time and the presumed mechanism is described in detail. An unexpected hydrogenation of the phthalimide group was also observed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.carres.2004.03.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phthalimide-Functionalized Heptamethine Cyanine Dye for Tumor-Targeted Photothermal Therapy.
Cancers (Basel)
December 2024
Department of Biomedical Sciences, Chonnam National University Medical School, Hwasun 58128, Republic of Korea.
Background: A phthalimide-functionalized heptamethine cyanine dye, named Ph790H, is used for targeted photothermal cancer therapy in vivo. We highlight that the chemical structure of Ph790H is newly designed and synthesized for the first time in this study.
Objectives: By possessing a rigid chloro-cyclohexenyl ring in the heptamethine cyanine backbone, the bifunctional near-infrared (NIR) fluorescent dye Ph790H can be preferentially accumulated in tumor without the need for additional targeting ligands, which is defined as the "structure-inherent tumor targeting" concept.
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
Lancet Haematol
January 2025
University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes.
Methods: In the ongoing, phase 3, open-label CARTITUDE-4 study, patients were recruited from 81 sites in the USA, Europe, Asia, and Australia, and were randomly assigned 1:1 to cilta-cel (target, 0·75 × 10 CAR-T cells/kg) or standard of care (daratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone).
SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy.
Front Immunol
January 2025
Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Introduction: Multiple myeloma (MM) is an uncontrolled plasma cell proliferation in the bone marrow, leading to immune dysregulation with impaired humoral immune responses. Conversely, cellular-based responses play a vital role in MM patients. However, the extent and duration of cellular-induced protection remain unclear to date.
View Article and Find Full Text PDF[Changes in Neutrophil Percentage-to-Albumin Ratio and Its Relationship with Short-Term Prognosis in Patients with Multiple Myeloma Treated with VRD].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Hematology, Tangshan Workers Hospital, Tangshan 063003, Hebei Province, China.
Article Synopsis
- The study aimed to evaluate how the neutrophil percentage-to-albumin ratio (NPAR) changes during treatment with bortezomib-lenalidomide-dexamethasone (VRD) in multiple myeloma patients and its relationship with patient prognosis.
- Researchers analyzed data from 80 multiple myeloma patients who underwent VRD treatment over two years, measuring NPAR at various stages of the chemotherapy cycles and following patient outcomes for one year.
- Results indicated that patients with poorer short-term prognosis had higher NPAR levels and lower albumin levels compared to those with better prognosis, suggesting NPAR could be a potential indicator of treatment outcomes in multiple myeloma.
Lenalidomide regulates the CCL21/CCR7/ERK1/2 axis to inhibit migration and proliferation in diffuse large B-cell lymphoma.
Oncol Res
December 2024
Department of Pathology, Guizhou Medical University, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
Background: The prognostic significance of the chemokine receptor CCR7 in diffuse large B-cell lymphoma (DLBCL) has been reported previously. However, the detailed mechanisms of CCR7 in DLBCL, particularly regarding its interaction with lenalidomide treatment, are not fully understood.
Methods: Our study utilized bioinformatics approaches to identify hub genes in SU-DHL-2 cell lines treated with lenalidomide compared to control groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!